OBJECTIVE: This study aimed to validate the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, English version 3.0) in Singaporean cancer patients. METHODS: In a cross-sectional study, a heterogeneous sample of cancer patients (n = 57) self-administered a questionnaire containing the QLQ-C30, the Short Form 36 Health Survey (SF-36) and assessing health and sociodemographic status. Construct validity was assessed by testing a priori hypotheses that QLQ-C30 scales would be moderately or strongly correlated with SF-36 scales measuring similar dimensions of health-related quality of life (HRQoL) and that subjects reporting mild symptoms would have better HRQoL scores than those reporting severe symptoms. Internal consistency reliability was assessed using Cronbach's alpha. RESULTS: Strength of Spearman's correlations between the QLQ-C30 and SF-36 scales assessing similar dimensions of HRQoL ranged from 0.35 to 0.67. Subjects with mild symptoms had better scores than those with severe symptoms for all six QLQ-C30 HRQoL scales (p < 0.05 for five scales, Mann-Whitney U tests). Cronbach's alpha ranged from 0.19 for the cognitive functioning scale to 0.91 for the global QoL scale. CONCLUSION: This study provides preliminary evidence for the validity and reliability of the EORTC QLQ-C30 in English-speaking Singaporean cancer patients.
OBJECTIVE: This study aimed to validate the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, English version 3.0) in Singaporean cancerpatients. METHODS: In a cross-sectional study, a heterogeneous sample of cancerpatients (n = 57) self-administered a questionnaire containing the QLQ-C30, the Short Form 36 Health Survey (SF-36) and assessing health and sociodemographic status. Construct validity was assessed by testing a priori hypotheses that QLQ-C30 scales would be moderately or strongly correlated with SF-36 scales measuring similar dimensions of health-related quality of life (HRQoL) and that subjects reporting mild symptoms would have better HRQoL scores than those reporting severe symptoms. Internal consistency reliability was assessed using Cronbach's alpha. RESULTS: Strength of Spearman's correlations between the QLQ-C30 and SF-36 scales assessing similar dimensions of HRQoL ranged from 0.35 to 0.67. Subjects with mild symptoms had better scores than those with severe symptoms for all six QLQ-C30 HRQoL scales (p < 0.05 for five scales, Mann-Whitney U tests). Cronbach's alpha ranged from 0.19 for the cognitive functioning scale to 0.91 for the global QoL scale. CONCLUSION: This study provides preliminary evidence for the validity and reliability of the EORTC QLQ-C30 in English-speaking Singaporean cancerpatients.
Authors: K Kobayashi; F Takeda; S Teramukai; I Gotoh; H Sakai; S Yoneda; Y Noguchi; H Ogasawara; K Yoshida Journal: Eur J Cancer Date: 1998-05 Impact factor: 9.162
Authors: A Montazeri; I Harirchi; M Vahdani; F Khaleghi; S Jarvandi; M Ebrahimi; M Haji-Mahmoodi Journal: Support Care Cancer Date: 1999-11 Impact factor: 3.603
Authors: K Bjordal; A de Graeff; P M Fayers; E Hammerlid; C van Pottelsberghe; D Curran; M Ahlner-Elmqvist; E J Maher; J W Meyza; A Brédart; A L Söderholm; J J Arraras; J S Feine; H Abendstein; R P Morton; T Pignon; P Huguenin; A Bottomly; S Kaasa Journal: Eur J Cancer Date: 2000-09 Impact factor: 9.162
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Johannes Mischinger; Mohamed F Abdelhafez; Tilman Todenhöfer; Christian Schwentner; Stefan Aufderklamm; Arnulf Stenzl; Georgios Gakis Journal: World J Urol Date: 2014-12-11 Impact factor: 4.226
Authors: Bello Arkilla Magaji; Foong Ming Moy; April Camilla Roslani; Ismail Sagap; Jasiah Zakaria; Jane M Blazeby; Chee Wei Law Journal: BMC Cancer Date: 2012-09-03 Impact factor: 4.430
Authors: Aisha S Sie; Liesbeth Spruijt; Wendy A G van Zelst-Stams; Arjen R Mensenkamp; Marjolijn J Ligtenberg; Han G Brunner; Judith B Prins; Nicoline Hoogerbrugge Journal: BMC Womens Health Date: 2012-05-08 Impact factor: 2.809